NCT02982850View on ClinicalTrials.gov

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Atrial FibrillationValve Heart Disease
Interventions
DRUG

Dabigatran

DRUG

Acetylsalicylic acid

DRUG

Warfarin

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Asan Medical Center

OTHER